Adult-onset autoimmune (AOA) diabetes pathophysiology starts with immune changes, followed by dysglycaemia and overt disease. AOA diabetes can occur as classic type 1 diabetes when associated with severe loss of insulin secretion. More frequently, it is diagnosed as latent autoimmune diabetes in adults, a slowly progressing form with late onset, a long period not requiring insulin, and it is often misdiagnosed as type 2 diabetes. As its clinical presentation varies remarkably and immune markers often lack specificity, it is challenging to classify each case ad hoc, especially when insulin treatment is not required at diagnosis. Proper care of AOA diabetes aims to prevent complications and to improve quality of life and life expectancy. To achieve these goals, attention should be paid to lifestyle factors, with the aid of pharmacological therapies properly tailored to each individual clinical setting. Given the heterogeneity of the disease, choosing the right therapy for AOA diabetes is challenging. Most of the trials testing disease-modifying therapies for autoimmune diabetes are conducted in people with childhood onset, whereas non-insulin diabetes therapies have mostly been studied in the larger population with type 2 diabetes. More randomized controlled trials of therapeutic agents in AOA diabetes are needed.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes — 2022. Diabetes Care 45 (Suppl. 1), S17–S38 (2021).
Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
Leslie, R. D. et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care 44, 2449–2456 (2021). An up-to-date authoritative review of the pathogenesis, characteristics, clinical and psychosocial impact and putative management of AOA diabetes.
Howson, J. M., Rosinger, S., Smyth, D. J., Boehm, B. O. & Todd, J. A., ABDW-END Study Group. Genetic analysis of adult-onset autoimmune diabetes. Diabetes 60, 2645–2653 (2011).
Mishra, R. et al. Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diabetes Care 43, 418–425 (2020).
Hawa, M. I. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 36, 908–913 (2013). Report from the large European Action LADA cohort pinpointing the major overlap between LADA- and T2DM-associated clinical phenotypes.
Maddaloni, E. et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS ONE 10, e0131837 (2015).
IDF. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021).
Diaz-Valencia, P. A., Bougnères, P. & Valleron, A. J. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 15, 255 (2015).
Harding, J. L. et al. The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care 45, 994–1006 (2022).
Xiang, Y. et al. Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey. Diabetes Obes. Metab. 2, 893–902 (2019).
Sheehan, A., Freni Sterrantino, A., Fecht, D., Elliott, P. & Hodgson, S. Childhood type 1 diabetes: an environment-wide association study across England. Diabetologia 63, 964–976 (2020).
Shields, B. M. et al. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open 5, e009088 (2015).
Thomas, N. J. et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 62, 1167–1172 (2019).
Jones, A. G., McDonald, T. J., Shields, B. M., Hagopian, W. & Hattersley, A. T. Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care 44, 1243–1251 (2021). Provides a cogent argument for better classification to facilitate improved assignment of prognosis and therapy in persons with adult-onset diabetes.
Gu, Y. et al. Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes. Diabetologia 64, 2052–2060 (2021).
Kawasaki, E. et al. Discrepancy of glutamic acid decarboxylase 65 autoantibody results between RSR radioimmunoassay and enzyme-linked immunosorbent assay in patients with type 1 diabetes is related to autoantibody affinity. J. Diabetes Investig. 10, 990–996 (2019).
Kawasaki, E. et al. Characterization of patients with diabetes who were incidentally found to be glutamic acid decarboxylase autoantibody-positive by bridging-type enzyme-linked immunosorbent assay. J. Diabetes Investig. 11, 1507–1510 (2020).
Tsirogianni, A., Pipi, E. & Soufleros, K. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun. Rev. 8, 687–691 (2009).
Zampetti, S. et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J. Clin. Endocrinol. Metab. 97, 3759–3765 (2012).
Gambelunghe, G. et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin. Endocrinol. 52, 565–573 (2000).
Zhu, M. et al. Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study. Diabetes Care 42, 1414–1421 (2019).
Oram, R. A. et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39, 337–344 (2016).
Mishra, R. et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med. 15, 88 (2017).
Carlsson, S. Environmental (lifestyle) risk factors for LADA. Curr. Diabetes Rev. 15, 178–187 (2019).
Hjort, R. et al. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study. Diabetologia 61, 1333–1343 (2018).
Hjort, R. et al. Family history of type 1 and type 2 diabetes and risk of latent autoimmune diabetes in adults (LADA). Diabetes Metab. 43, 536–542 (2017).
Herzog, K. et al. Combined lifestyle factors and the risk of LADA and type 2 diabetes–results from a Swedish population-based case-control study. Diabetes Res. Clin. Pract. 174, 108760 (2021). Population-based study from Sweden showing that a healthy lifestyle, especially a healthy body weight, is reducing the risk of LADA including in those with a positive family history of diabetes and/or high-risk HLA genotypes.
Buzzetti, R., Zampetti, S. & Pozzilli, P. Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes Obes. Metab. 22, 1009–1013 (2020).
Censin, J. C. et al. Childhood adiposity and risk of type 1 diabetes: a Mendelian randomization study. PLoS Med. 14, e1002362 (2017).
Lofvenborg, J. E. et al. Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Eur. J. Endocrinol. 175, 605–614 (2016).
Löfvenborg, J. E. et al. Consumption of red meat, genetic susceptibility, and risk of LADA and type 2 diabetes. Eur. J. Nutr. 60, 769–779 (2021).
Rasouli, B. et al. Alcohol and the risk for latent autoimmune diabetes in adults: results based on Swedish ESTRID study. Eur. J. Endocrinol. 171, 535–543 (2014).
In’t Veld, P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 3, 131–138 (2011).
Fasolino, M. et al. Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes. Nat. Metab. 4, 284–299 (2022).
Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964–1974 (2015).
Garcia, T. S., Rech, T. H. & Leitão, C. B. Pancreatic size and fat content in diabetes: a systematic review and meta-analysis of imaging studies. PLoS ONE 12, e0180911 (2017).
Lu, J. et al. Pancreatic volume is reduced in patients with latent autoimmune diabetes in adults. Diabetes Metab. Res. Rev. 32, 858–866 (2016).
Subauste, A. et al. Islet autoimmunity identifies a unique pattern of impaired pancreatic beta-cell function, markedly reduced pancreatic beta cell mass and insulin resistance in clinically diagnosed type 2 diabetes. PLoS ONE 9, e106537 (2014).
Campbell-Thompson, M. et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 65, 719–731 (2016).
Leete, P. et al. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 65, 1362–1369 (2016).
Signore, A. et al. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care 38, 652–658 (2015).
Jörns, A., Wedekind, D., Jähne, J. & Lenzen, S. Pancreas pathology of latent autoimmune diabetes in adults (LADA) in patients and in a LADA rat model compared with type 1 diabetes. Diabetes 69, 624–633 (2020).
Brooks-Worrell, B. M., Reichow, J. L., Goel, A., Ismail, H. & Palmer, J. P. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 34, 168–173 (2011).
Brooks-Worrell, B. M., Boyko, E. J. & Palmer, J. P. Impact of islet autoimmunity on the progressive β-cell functional decline in type 2 diabetes. Diabetes Care 37, 3286–3293 (2014).
Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K. & Morgan, N. G. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52, 1143–1151 (2009).
Krogvold, L. et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64, 1682–1687 (2015).
Nigi, L. et al. Increased expression of viral sensor MDA5 in pancreatic islets and in hormone-negative endocrine cells in recent onset type 1 diabetic donors. Front. Immunol. 13, 833141 (2022).
Buzzetti, R. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30, 932–938 (2007).
Zampetti, S. et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur. J. Endocrinol. 171, 697–704 (2014). Follow-up study defining high GADA titre, BMI ≤25, ZnT8, IA-2IC positivity and sulfonylurea treatment as significant risks to progression towards insulin requirement in LADA.
Kawasaki, E. et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 43, 80–86 (1994).
Achenbach, P. et al. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia 61, 1644–1649 (2018).
Tiberti, C. et al. Immunoreactivities against different tyrosine-phosphatase 2 (IA-2) (256-760) protein domains characterize distinct phenotypes in subjects With LADA. Front. Endocrinol. 13, 921886 (2022).
Smilek, D. E., Ehlers, M. R. & Nepom, G. T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis. Model. Mech. 7, 503–513 (2014).
James, E. A., Pietropaolo, M. & Mamula, M. J. Immune recognition of β-cells: neoepitopes as key players in the loss of tolerance. Diabetes 67, 1035–1042 (2018).
Gootjes, C., Zwaginga, J. J., Roep, B. O. & Nikolic, T. Functional impact of risk gene variants on the autoimmune responses in type 1 diabetes. Front. Immunol. 13, 886736 (2022).
Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).
Maine, C. J. et al. PTPN22 alters the development of regulatory T cells in the thymus. J. Immunol. 188, 5267–5275 (2012).
Hull, C. M., Peakman, M. & Tree, T. I. M. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? Diabetologia 60, 1839–1850 (2017).
Schneider, A. et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+FOXP3+ regulatory T cells. J. Immunol. 181, 7350–7355 (2008).
Radenkovic, M. et al. Altered regulatory T cell phenotype in latent autoimmune diabetes of the adults (LADA). Clin. Exp. Immunol. 186, 46–56 (2016).
Yang, Z. et al. The CD4+ regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res. Clin. Pract. 76, 126–131 (2007).
Wang, X. et al. Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: a 1-year open-label randomized controlled trial. J. Diabetes Investig. 10, 375–382 (2019).
Kemppainen, K. M. et al. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Diabetes Care 38, 329–332 (2015).
Fang, Y. et al. Characteristics of the gut microbiota and metabolism in patients with latent autoimmune diabetes in adults: a case-control study. Diabetes Care 44, 2738–2746 (2021). This paper highlights the finding that the structure and composition of the gut microbiota from individuals with LADA differed from those of individuals with T1DM and T2DM.
Kim, C. H. Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol. Immunol. 18, 1161–1171 (2021).
Vatanen, T. et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562, 589–594 (2018).
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99–103 (2013).
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018). This paper reviews immune-mediated adverse events that have occurred with new powerful immunotherapeutic treatments for cancers, which include diabetes associated with these treatments.
Tachibana, M. & Imagawa, A. Type 1 diabetes related to immune checkpoint inhibitors. Best Pract. Res. Clin. Endocrinol. Metab. 36, 101657 (2022).
Quandt, Z., Young, A. & Anderson, M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin. Exp. Immunol. 200, 131–140 (2020).
Liu, J. et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015–2019. Diabetes Care 43, e79–e80 (2020).
Abarca-Gómez, L. et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390, 2627–2642 (2017).
Tuomi, T. et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48, 150–157 (1999).
Carlsson, S. Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type 2 diabetes. Front. Physiol. 10, 320 (2019).
Buzzetti, R., Zampetti, S. & Maddaloni, E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat. Rev. Endocrinol. 13, 674–686 (2017).
Zaharia, O. P. et al. Metabolic characteristics of recently diagnosed adult-onset autoimmune diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 429–437 (2018).
Tuomi, T. et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42, 359–362 (1993).
Genovese, S. et al. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol. 154, 441–447 (2006).
Pozzilli, P. & Pieralice, S. Latent autoimmune diabetes in adults: current status and new horizons. Endocrinol. Metab. 33, 147–159 (2018).
Zinman, B. et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53, 3193–3200 (2004).
Zhou, Z. et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62, 543–550 (2013).
Ong, Y. H. et al. Glutamic acid decarboxylase and islet antigen 2 antibody profiles in people with adult-onset diabetes mellitus: a comparison between mixed ethnic populations in Singapore and Germany. Diabet. Med. 34, 1145–1153 (2017). Transethnic study comparing immunological and clinical features of patients with LADA from Europe and from three ethnic groups from Singapore.
Adeleye, O. O. et al. Latent autoimmune diabetes mellitus in adults (LADA) and its characteristics in a subset of Nigerians initially managed for type 2 diabetes. Int. Arch. Med. 5, 23 (2012).
Davies, H. et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabet. Med. 25, 1354–1357 (2008). First study of LADA in primary care, which describes a lower BMI, the presence of other antibodies, the presence of acute diabetes symptoms and higher glycated haemoglobin in incident LADA cases.
Szepietowska, B., Glebocka, A., Puch, U., Gorska, M. & Szelachowska, M. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Arch. Med. Sci. 8, 491–495 (2012).
Carlsson, S., Midthjell, K., Tesfamarian, M. Y. & Grill, V. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trondelag health study. Diabetologia 50, 55–58 (2007).
Hernandez, M. et al. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: Action LADA 9. BMC Endocr. Disord. 15, 1 (2015).
Bacha, F. & Redondo, M. J. Decline pattern of beta cell function in LADA: relationship to GAD autoantibodies. J. Clin. Endocrinol. Metab. 105, e3008–e3009 (2020).
Donnelly, L. A. et al. Rates of glycaemic deterioration in a real-world population with type 2 diabetes. Diabetologia 61, 607–615 (2018).
Buzzetti, R. et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 69, 2037–2047 (2020). First intenational consensus statement providing guidance for the treatment of LADA.
Andersen, C. D. et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 56, 252–258 (2013).
Chow, L. S., Chen, H., Miller, M. E., Marcovina, S. M. & Seaquist, E. R. Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia 58, 1160–1166 (2015). Nested case–control analysis from the ACCORD study identifying low C-peptide and the presence of islet autoantibodies as potential risks of severe hypoglycaemia with near-normal glycaemia as treatment target.
Maioli, M. et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. Eur. J. Endocrinol. 163, 541–549 (2010).
Petrone, A. et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: non insulin requiring autoimmune diabetes (NIRAD) study 3. Diabetes Care 31, 534–538 (2008).
Zampetti, S. et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD study 5). Diabet. Med. 27, 701–704 (2010).
Tiberti, C. et al. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes 57, 1276–1283 (2008).
Buzzetti, R. et al. Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care 38, 513–520 (2015).
Tiberti, C. et al. Evidence of diabetes-specific autoimmunity in obese subjects with normal glucose tolerance. Diabetes Metab. Res. Rev. 34, e3055 (2018).
Andersen, M. K. et al. Zinc transporter type 8 autoantibodies (ZnT8A): prevalence and phenotypic associations in latent autoimmune diabetes patients and patients with adult onset type 1 diabetes. Autoimmunity 46, 251–258 (2013).
Sørgjerd, E. P., Skorpen, F., Kvaløy, K., Midthjell, K. & Grill, V. Prevalence of ZnT8 antibody in relation to phenotype and SLC30A8 polymorphism in adult autoimmune diabetes: results from the HUNT study, Norway. Autoimmunity 46, 74–79 (2013).
Fourlanos, S. et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48, 2206–2212 (2005).
Tanaka, S. et al. Clinical characteristics of slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM): 1st Subcommittee Report on SPIDDM, Committee on Type 1 Diabetes, Japan Diabetes Society. Journal of the Japan Diabetes Society 54, 65–75 (2011).
Araki, E. et al. Japanese clinical practice guideline for diabetes 2019. J. Diabetes Investig. 11, 1020–1076 (2020).
WHO. Classification of Diabetes Mellitus 2019 (WHO, 2019).
Chung, W. K. et al. Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 1671–1693 (2020).
Tuomi, T. et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383, 1084–1094 (2014).
Bansal, V. et al. Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals. BMC Med. 15, 213 (2017).
Bonnefond, A. et al. Pathogenic variants in actionable MODY genes are associated with type 2 diabetes. Nat. Metab. 2, 1126–1134 (2020).
Holt, R. I. G. et al. The management of type 1 diabetes in adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 44, 2589–2625 (2021).
Magkos, F., Hjorth, M. F. & Astrup, A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 16, 545–555 (2020).
McGee, S. L. & Hargreaves, M. Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit. Nat. Rev. Endocrinol. 16, 495–505 (2020).
Pieralice, S., Vigevano, F., Del Toro, R., Napoli, N. & Maddaloni, E. Lifestyle management of diabetes: implications for the bone-vascular axis. Curr. Diab. Rep. 18, 84 (2018).
Chimen, M. et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 55, 542–551 (2012).
Fiuza-Luces, C. et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat. Rev. Cardiol. 15, 731–743 (2018).
Wake, A. D. Protective effects of physical activity against health risks associated with type 1 diabetes: “Health benefits outweigh the risks”. World J. Diabetes 13, 161–184 (2022).
Wu, N. et al. Cardiovascular health benefits of exercise training in persons living with type 1 diabetes: a systematic review and meta-analysis. J. Clin. Med. 8, 253 (2019).
Tikkanen-Dolenc, H. et al. Physical activity reduces risk of premature mortality in patients with type 1 diabetes with and without kidney disease. Diabetes Care 40, 1727–1732 (2017).
Maddaloni, E., Moretti, C., Mignogna, C. & Buzzetti, R. Adult-onset autoimmune diabetes in 2020: an update. Maturitas 137, 37–44 (2020).
Maddaloni, E. et al. C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes. Metab. https://doi.org/10.1111/dom.14785 (2022).
Brophy, S., Davies, H., Mannan, S., Brunt, H. & Williams, R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst. Rev. 9, CD006165 (2011).
Maddaloni, E., Coleman, R. L., Pozzilli, P. & Holman, R. R. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes. Metab. 21, 2115–2122 (2019).
Group, I. H. S. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 7, 385–396 (2019).
Panzer, J. K. & Caicedo, A. Targeting the pancreatic α-cell to prevent hypoglycemia in type 1 diabetes. Diabetes 70, 2721–2732 (2021).
Bell, K. J., Barclay, A. W., Petocz, P., Colagiuri, S. & Brand-Miller, J. C. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2, 133–140 (2014).
Vaz, E. C., Porfírio, G. J. M., Nunes, H. R. C. & Nunes-Nogueira, V. D. S. Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Arch. Endocrinol. Metab. 62, 337–345 (2018).
Zheng, H. et al. Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 38, e3515 (2022).
Van der Schueren, B. et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 9, 776–785 (2021).
Cree-Green, M. et al. Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes. J. Clin. Endocrinol. Metab. 104, 3265–3278 (2019).
Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017).
Natali, A. & Ferrannini, E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49, 434–441 (2006).
Yang, Z., Zhou, Z., Li, X., Huang, G. & Lin, J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res. Clin. Pract. 83, 54–60 (2009).
Zhou, Z. et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 21, 203–208 (2005).
Dennis, J. M. et al. Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care 41, 1844–1853 (2018).
Shimada, A. et al. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab. Res. Rev. 27, 951–953 (2011).
Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019).
Farilla, L. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149–5158 (2003).
von Herrath, M. et al. Anti-interleukin-21 antibodyand liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 212–224 (2021).
Pozzilli, P. et al. Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes. J. Clin. Endocrinol. Metab. 105, dgaa149 (2020).
Pozzilli, P. et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials. Diabetes Obes. Metab. 20, 1490–1498 (2018).
Jones, A. G. et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39, 250–257 (2016).
Ceriello, A., Sportiello, L., Rafaniello, C. & Rossi, F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin. Drug Saf. 13, S57–S68 (2014).
Awata, T. et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 8, 1123–1134 (2017).
Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N. & Hirshberg, B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab. Res. Rev. 32, 289–296 (2016).
Johansen, O. E. et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 37, e11–e12 (2014).
Zhao, Y. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J. Clin. Endocrinol. Metab. 99, e876–e880 (2014).
Yang, L. et al. Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: a randomized trial. J. Clin. Endocrinol. Metab. 106, e1529–e1541 (2021).
Zhang, Z. et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: a 1-year pilot study. Diabetes Metab. Res. Rev. 36, e3298 (2020).
Hals, I. K. et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: results from a 21-month randomized trial. Diabetes Obes. Metab. 21, 2219–2227 (2019).
Mathieu, C. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care 41, 1938–1946 (2018).
Dandona, P. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 5, 864–876 (2017).
Garg, S. K. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N. Engl. J. Med. 377, 2337–2348 (2017).
Kaku, K., Isaka, H., Sakatani, T. & Toyoshima, J. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial. Diabetes Obes. Metab. 21, 2284–2293 (2019).
Medicines and Healthcare products Regulatory Agency. Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus. Medicines and Healthcare products Regulatory Agency https://www.gov.uk/drug-safety-update/dapagliflozin-forxiga-no-longer-authorised-for-treatment-of-type-1-diabetes-mellitus (2021).
Mathieu, C. et al. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2. Diabetes Obes. Metab. 22, 2151–2160 (2020).
Danne, T. et al. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥27 kg/m2. Diabetes Obes. Metab. 23, 854–860 (2021).
Whitehouse, F. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25, 724–730 (2002).
Pozzilli, P., Maddaloni, E. & Buzzetti, R. Combination immunotherapies for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 11, 289–297 (2015).
Mignogna, C., Maddaloni, E., D’Onofrio, L. & Buzzetti, R. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opin. Investig. Drugs 30, 1209–1219 (2021).
Agardh, C. D., Lynch, K. F., Palmér, M., Link, K. & Lernmark, A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52, 1363–1368 (2009).
Gitelman, S. E. et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 502–514 (2021).
Bradley, C. et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual. Life Res. 8, 79–91 (1999).
Bradley, C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes care 22, 530–532 (1999).
Ahola, A. J. et al. Health-related quality of life in patients with type 1 diabetes-association with diabetic complications (the FinnDiane study). Nephrol. Dial. Transpl. 25, 1903–1908 (2010).
Driscoll, K. A. et al. Biopsychosocial aspects of weight management in type 1 diabetes: a review and next steps. Review. Curr. Diabetes Rep. 17, 58 (2017).
Hassan, K., Loar, R., Anderson, B. J. & Heptulla, R. A. The role of socioeconomic status, depression, quality of life, and glycemic control in type 1 diabetes mellitus. J. Pediatr. 149, 526–531 (2006).
Granado-Casas, M. et al. Decreased quality of life and treatment satisfaction in patients with latent autoimmune diabetes of the adult. PeerJ 5, e3928 (2017). Directly addresses QoL and treatment satisfaction in persons with LADA compared with those with classic T1DM and T2DM.
Fadiga, L. et al. Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation. Diabetol. Metab. Syndr. 12, 107 (2020).
Maddaloni, E., Coleman, R. L., Agbaje, O., Buzzetti, R. & Holman, R. R. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 8, 206–215 (2020). Post-hoc analysis of the UKPDS comparing the long-term risk of microvascular complications between people with LADA and people with T2DM.
Tanaka, S. et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM)(2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol. Int. 6, 1–7 (2015).
Lohmann, T. et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44, 1005–1010 (2001).
Li, X., Yang, L., Zhou, Z., Huang, G. & Yan, X. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults. Comparative Study. Chin. Med. J. 116, 1728–1732 (2003).
Aoyama, T. et al. Clinical heterogeneity of adult Japanese diabetes depending on titers of glutamic acid decarboxylase autoantibodies. J. Diabetes Invest. 3, 266–270 (2012).
Laugesen, E., Østergaard, J. A. & Leslie, R. D. G. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet. Med. 32, 843–852 (2015).
University of Exeter. T1DT2D Prediction Model. Diabetes Genes https://www.diabetesgenes.org/t1dt2d-prediction-model/ (2022).
Goel, A., Chiu, H., Felton, J., Palmer, J. P. & Brooks-Worrell, B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes. Diabetes 56, 2110–2115 (2007).
Liang, H. et al. Clinical manifestation and islet beta-cell function of a subtype of latent autoimmune diabetes in adults (LADA): positive for T cell responses in phenotypic type 2 diabetes. Acta Diabetol. 56, 1225–1230 (2019).
Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 Diabetes TrialNet data. Diabetes 61, 2066–2073 (2012).
Mortensen, H. B. et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32, 1384–1390 (2009).
Zhong, T. et al. The remission phase in type 1 diabetes: changing epidemiology, definitions, and emerging immuno-metabolic mechanisms. Diabetes Metab. Res. Rev. 36, e3207 (2020).
Takeda, H. et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime study). Diabetes Care 25, 995–1001 (2002).
Turner, R. et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350, 1288–1293 (1997).
Radtke, M. A., Midthjell, K., Nilsen, T. I. & Grill, V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trøndelag Health (HUNT) study. Diabetes Care 32, 245–250 (2009).
Qi, X. et al. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care 34, 66–70 (2011).
Agyei-Frempong, M. T., Titty, F. V., Owiredu, W. K. & Eghan, B. A. The prevalence of autoimmune diabetes among diabetes mellitus patients in Kumasi, Ghana. Pak. J. Biol. Sci. 11, 2320–2325 (2008).
Muazu, S. B., Okpe, I. & Anumah, F. The prevalence and characteristics of latent autoimmune diabetes in adults subset among type two diabetes mellitus patients in northern Nigeria. Ann. Afr. Med. 15, 163–170 (2016).
Al-Zubairi, T., Al-Habori, M. & Saif-Ali, R. Latent autoimmune diabetes in adults (LADA) and its metabolic characteristics among yemeni type 2 diabetes mellitus patients. Diabetes Metab. Syndr. Obes. 14, 4223–4232 (2021).
Jónsdóttir, A. M., Aspelund, T., Sigurdsson, G., Gudnason, V. & Benediktsson, R. Latent autoimmune diabetes in adults in Iceland: prevalence, phenotype and relatedness [Icelandic]. Laeknabladid 91, 909–914 (2005).
Brahmkshatriya, P. P., Mehta, A. A., Saboo, B. D. & Goyal, R. K. Characteristics and prevalence of latent autoimmune diabetes in adults (LADA). ISRN Pharmacol. 2012, 580202 (2012).
Roh, M. O., Jung, C. H., Kim, B. Y., Mok, J. O. & Kim, C. H. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol. 50, 129–134 (2013).
Davis, T. M. E. & Davis, W. Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. BMJ Open Diabetes Res. Care 8, e000983 (2020).
Dhatariya, K. K., Glaser, N. S., Codner, E. & Umpierrez, G. E. Diabetic ketoacidosis. Nat. Rev. Dis. Primers 6, 40 (2020).
Kalscheuer, H. et al. Event rates and risk factors for the development of diabetic ketoacidosis in adult patients with type 1 diabetes: analysis from the DPV registry based on 46,966 patients. Diabetes Care 42, e34–e36 (2019).
Weinstock, R. S. et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry. J. Clin. Endocrinol. Metab. 98, 3411–3419 (2013).
Fazeli Farsani, S. et al. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open 7, e016587 (2017).
Alam, U. et al. Latent autoimmune diabetes of adulthood (LADA) is associated with small fibre neuropathy. Diabet. Med. 36, 1118–1124 (2019).
D’Onofrio, L. et al. Small nerve fiber damage and langerhans cells in type 1 and type 2 diabetes and LADA measured by corneal confocal microscopy. Invest. Ophthalmol. Vis. Sci. 62, 5 (2021).
Baum, P. et al. Diabetic neuropathy in patients with “latent autoimmune diabetes of the adults” (LADA) compared with patients with type 1 and type 2 diabetes. J. Neurol. 250, 682–687 (2003).
Maddaloni, E. et al. Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: a cross-sectional study. Diabet. Med. 38, e14455 (2021).
R.B. was supported by the Italian Ministry of Universities and Research (Project of National Interest–PRIN, #20175L9H7H) and by the Research Foundation of the Italian Society of Diabetology (SID). B.O.B. was supported by the Ministry of Education, Singapore, Ong Tiong Tat Chair Professorship, Boehringer Ingelheim, Ulm University Bio Center (BIU) and Deutsche Forschungsgemeinschaft (DFG) (SFB 518, GRK 104).
R.B. declares consulting for Sanofi, Novo Nordisk and Eli Lilly; and receiving honoraria for speaker bureaux from AstraZeneca and Abbott. J.G. declares consulting for Vertex Pharmaceuticals, Inc., Dompé farmaceutici and Avotres, Inc. E.M. declares consulting for Merck KGaA and PikDare; and receiving honoraria as speaker from Abbott. R.D.L., F.S.W. and B.O.B. declare no competing interests.
Peer review information
Nature Reviews Disease Primers thanks A. Michels, who co-reviewed with A. Mitchell; E. Kawasaki; L. Harrison; J. Størling; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Buzzetti, R., Maddaloni, E., Gaglia, J. et al. Adult-onset autoimmune diabetes. Nat Rev Dis Primers 8, 63 (2022). https://doi.org/10.1038/s41572-022-00390-6